schliessen

Filtern

 

Bibliotheken

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

Menopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome‐wide association studies. The interp... Full description

Journal Title: International Journal of Cancer 15 December 2016, Vol.139(12), pp.2646-2654
Main Author: Lee, Alice W.
Other Authors: Bomkamp, Ashley , Bandera, Elisa V. , Jensen, Allan , Ramus, Susan J. , Goodman, Marc T. , Rossing, Mary Anne , Modugno, Francesmary , Moysich, Kirsten B. , Chang‐Claude, Jenny , Rudolph, Anja , Gentry‐Maharaj, Aleksandra , Terry, Kathryn L. , Gayther, Simon A. , Cramer, Daniel W. , Doherty, Jennifer A. , Schildkraut, Joellen M. , Kjaer, Susanne K. , Ness, Roberta B. , Menon, Usha , Berchuck, Andrew , Mukherjee, Bhramar , Roman, Lynda , Pharoah, Paul D. , Chenevix‐Trench, Georgia , Olson, Sara , Hogdall, Estrid , Wu, Anna H. , Pike, Malcolm C. , Stram, Daniel O. , Pearce, Celeste Leigh
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0020-7136 ; E-ISSN: 1097-0215 ; DOI: 10.1002/ijc.30274
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wj10.1002/ijc.30274
title: A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
format: Article
creator:
  • Lee, Alice W.
  • Bomkamp, Ashley
  • Bandera, Elisa V.
  • Jensen, Allan
  • Ramus, Susan J.
  • Goodman, Marc T.
  • Rossing, Mary Anne
  • Modugno, Francesmary
  • Moysich, Kirsten B.
  • Chang‐Claude, Jenny
  • Rudolph, Anja
  • Gentry‐Maharaj, Aleksandra
  • Terry, Kathryn L.
  • Gayther, Simon A.
  • Cramer, Daniel W.
  • Doherty, Jennifer A.
  • Schildkraut, Joellen M.
  • Kjaer, Susanne K.
  • Ness, Roberta B.
  • Menon, Usha
  • Berchuck, Andrew
  • Mukherjee, Bhramar
  • Roman, Lynda
  • Pharoah, Paul D.
  • Chenevix‐Trench, Georgia
  • Olson, Sara
  • Hogdall, Estrid
  • Wu, Anna H.
  • Pike, Malcolm C.
  • Stram, Daniel O.
  • Pearce, Celeste Leigh
subjects:
  • Gene–Environment Interactions
  • Ovarian Cancer
  • Hormone Therapy
  • Estrogen
  • Snps
ispartof: International Journal of Cancer, 15 December 2016, Vol.139(12), pp.2646-2654
description: Menopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome‐wide association studies. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases and 4,051 controls across 10 case–control studies participating in the Ovarian Cancer Association Consortium (OCAC). Conditional logistic regression was used to determine the association between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer among ET users and non‐users separately and to test for statistical interaction. A splicing variant in , rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer ( = 0.013). ET users carrying the T allele had a 51% increased risk of disease (OR = 1.51, 95% CI 1.19–1.91), which was stronger for long‐term ET users of 10+ years (OR = 1.85, 95% CI 1.28–2.66,  = 0.034). Non‐users showed essentially no association (OR = 1.08, 95% CI 0.96–1.21). Two additional genomic regions harboring rs7207826 (C allele) and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid histotype ( = 0.021 and  = 0.037, respectively). Hence, three confirmed susceptibility variants were identified whose associations with ovarian cancer risk are modified by ET exposure; follow‐up is warranted given that these interactions are not adjusted for multiple comparisons. These findings, if validated, may elucidate the mechanism of action of these loci. What's new? Menopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, with 18 ovarian cancer susceptibility loci already confirmed. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. This study identifies three confirmed susceptibility variants whose associations with ovarian cancer risk are modified by ET exposure. Of particular interest is the interaction with rs10069690, a functional variant located in . The findings, if validated, may elucidate the mechanism of action of these loci and be critical for future risk prediction modeling.
language:
source:
identifier: ISSN: 0020-7136 ; E-ISSN: 1097-0215 ; DOI: 10.1002/ijc.30274
fulltext: fulltext
issn:
  • 0020-7136
  • 00207136
  • 1097-0215
  • 10970215
url: Link


@attributes
ID352907698
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1002/ijc.30274
sourceidwj
recordidTN_wj10.1002/ijc.30274
sourcesystemPC
pqid1828152018
galeid466338606
display
typearticle
titleA splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
creatorLee, Alice W. ; Bomkamp, Ashley ; Bandera, Elisa V. ; Jensen, Allan ; Ramus, Susan J. ; Goodman, Marc T. ; Rossing, Mary Anne ; Modugno, Francesmary ; Moysich, Kirsten B. ; Chang‐Claude, Jenny ; Rudolph, Anja ; Gentry‐Maharaj, Aleksandra ; Terry, Kathryn L. ; Gayther, Simon A. ; Cramer, Daniel W. ; Doherty, Jennifer A. ; Schildkraut, Joellen M. ; Kjaer, Susanne K. ; Ness, Roberta B. ; Menon, Usha ; Berchuck, Andrew ; Mukherjee, Bhramar ; Roman, Lynda ; Pharoah, Paul D. ; Chenevix‐Trench, Georgia ; Olson, Sara ; Hogdall, Estrid ; Wu, Anna H. ; Pike, Malcolm C. ; Stram, Daniel O. ; Pearce, Celeste Leigh
ispartofInternational Journal of Cancer, 15 December 2016, Vol.139(12), pp.2646-2654
identifier
subjectGene–Environment Interactions ; Ovarian Cancer ; Hormone Therapy ; Estrogen ; Snps
descriptionMenopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome‐wide association studies. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases and 4,051 controls across 10 case–control studies participating in the Ovarian Cancer Association Consortium (OCAC). Conditional logistic regression was used to determine the association between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer among ET users and non‐users separately and to test for statistical interaction. A splicing variant in , rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer ( = 0.013). ET users carrying the T allele had a 51% increased risk of disease (OR = 1.51, 95% CI 1.19–1.91), which was stronger for long‐term ET users of 10+ years (OR = 1.85, 95% CI 1.28–2.66,  = 0.034). Non‐users showed essentially no association (OR = 1.08, 95% CI 0.96–1.21). Two additional genomic regions harboring rs7207826 (C allele) and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid histotype ( = 0.021 and  = 0.037, respectively). Hence, three confirmed susceptibility variants were identified whose associations with ovarian cancer risk are modified by ET exposure; follow‐up is warranted given that these interactions are not adjusted for multiple comparisons. These findings, if validated, may elucidate the mechanism of action of these loci. What's new? Menopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, with 18 ovarian cancer susceptibility loci already confirmed. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. This study identifies three confirmed susceptibility variants whose associations with ovarian cancer risk are modified by ET exposure. Of particular interest is the interaction with rs10069690, a functional variant located in . The findings, if validated, may elucidate the mechanism of action of these loci and be critical for future risk prediction modeling.
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Lee, Alice W.
1Bomkamp, Ashley
2Bandera, Elisa V.
3Jensen, Allan
4Ramus, Susan J.
5Goodman, Marc T.
6Rossing, Mary Anne
7Modugno, Francesmary
8Moysich, Kirsten B.
9Chang‐Claude, Jenny
10Rudolph, Anja
11Gentry‐Maharaj, Aleksandra
12Terry, Kathryn L.
13Gayther, Simon A.
14Cramer, Daniel W.
15Doherty, Jennifer A.
16Schildkraut, Joellen M.
17Kjaer, Susanne K.
18Ness, Roberta B.
19Menon, Usha
20Berchuck, Andrew
21Mukherjee, Bhramar
22Roman, Lynda
23Pharoah, Paul D.
24Chenevix‐Trench, Georgia
25Olson, Sara
26Hogdall, Estrid
27Wu, Anna H.
28Pike, Malcolm C.
29Stram, Daniel O.
30Pearce, Celeste Leigh
titleA splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
descriptionMenopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome‐wide association studies. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases and 4,051 controls across 10 case–control studies participating in the Ovarian Cancer Association Consortium (OCAC). Conditional logistic regression was used to determine the association between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer among ET users and non‐users separately and to test for statistical interaction. A splicing variant in , rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer ( = 0.013). ET users carrying the T allele had a 51% increased risk of disease (OR = 1.51, 95% CI 1.19–1.91), which was stronger for long‐term ET users of 10+ years (OR = 1.85, 95% CI 1.28–2.66,  = 0.034). Non‐users showed essentially no association (OR = 1.08, 95% CI 0.96–1.21). Two additional genomic regions harboring rs7207826 (C allele) and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid histotype ( = 0.021 and  = 0.037, respectively). Hence, three confirmed susceptibility variants were identified whose associations with ovarian cancer risk are modified by ET exposure; follow‐up is warranted given that these interactions are not adjusted for multiple comparisons. These findings, if validated, may elucidate the mechanism of action of these loci. What's new? Menopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, with 18 ovarian cancer susceptibility loci already confirmed. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. This study identifies three confirmed susceptibility variants whose associations with ovarian cancer risk are modified by ET exposure. Of particular interest is the interaction with rs10069690, a functional variant located in . The findings, if validated, may elucidate the mechanism of action of these loci and be critical for future risk prediction modeling.
subject
0Gene–Environment Interactions
1Ovarian Cancer
2Hormone Therapy
3Estrogen
4Snps
general
010.1002/ijc.30274
1Wiley Online Library
sourceidwj
recordidwj10.1002/ijc.30274
issn
00020-7136
100207136
21097-0215
310970215
rsrctypearticle
creationdate2016
addtitle
0International Journal of Cancer
1Int. J. Cancer
searchscope
0wj
1wiley
scope
0wj
1wiley
lsr30VSR-Enriched:[pages, galeid, pqid]
sort
titleA splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
authorLee, Alice W. ; Bomkamp, Ashley ; Bandera, Elisa V. ; Jensen, Allan ; Ramus, Susan J. ; Goodman, Marc T. ; Rossing, Mary Anne ; Modugno, Francesmary ; Moysich, Kirsten B. ; Chang‐Claude, Jenny ; Rudolph, Anja ; Gentry‐Maharaj, Aleksandra ; Terry, Kathryn L. ; Gayther, Simon A. ; Cramer, Daniel W. ; Doherty, Jennifer A. ; Schildkraut, Joellen M. ; Kjaer, Susanne K. ; Ness, Roberta B. ; Menon, Usha ; Berchuck, Andrew ; Mukherjee, Bhramar ; Roman, Lynda ; Pharoah, Paul D. ; Chenevix‐Trench, Georgia ; Olson, Sara ; Hogdall, Estrid ; Wu, Anna H. ; Pike, Malcolm C. ; Stram, Daniel O. ; Pearce, Celeste Leigh
creationdate20161215
facets
frbrgroupid1976787480524594851
frbrtype5
creationdate2016
topic
0Gene–Environment Interactions
1Ovarian Cancer
2Hormone Therapy
3Estrogen
4Snps
collectionWiley Online Library
prefilterarticles
rsrctypearticles
creatorcontrib
0Lee, Alice W.
1Bomkamp, Ashley
2Bandera, Elisa V.
3Jensen, Allan
4Ramus, Susan J.
5Goodman, Marc T.
6Rossing, Mary Anne
7Modugno, Francesmary
8Moysich, Kirsten B.
9Chang‐Claude, Jenny
10Rudolph, Anja
11Gentry‐Maharaj, Aleksandra
12Terry, Kathryn L.
13Gayther, Simon A.
14Cramer, Daniel W.
15Doherty, Jennifer A.
16Schildkraut, Joellen M.
17Kjaer, Susanne K.
18Ness, Roberta B.
19Menon, Usha
20Berchuck, Andrew
21Mukherjee, Bhramar
22Roman, Lynda
23Pharoah, Paul D.
24Chenevix‐Trench, Georgia
25Olson, Sara
26Hogdall, Estrid
27Wu, Anna H.
28Pike, Malcolm C.
29Stram, Daniel O.
30Pearce, Celeste Leigh
jtitleInternational Journal of Cancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Lee
1Bomkamp
2Bandera
3Jensen
4Ramus
5Goodman
6Rossing
7Modugno
8Moysich
9Chang‐Claude
10Rudolph
11Gentry‐Maharaj
12Terry
13Gayther
14Cramer
15Doherty
16Schildkraut
17Kjaer
18Ness
19Menon
20Berchuck
21Mukherjee
22Roman
23Pharoah
24Chenevix‐Trench
25Olson
26Hogdall
27Wu
28Pike
29Stram
30Pearce
aufirst
0Alice W.
1Ashley
2Elisa V.
3Allan
4Susan J.
5Marc T.
6Mary Anne
7Francesmary
8Kirsten B.
9Jenny
10Anja
11Aleksandra
12Kathryn L.
13Simon A.
14Daniel W.
15Jennifer A.
16Joellen M.
17Susanne K.
18Roberta B.
19Usha
20Andrew
21Bhramar
22Lynda
23Paul D.
24Georgia
25Sara
26Estrid
27Anna H.
28Malcolm C.
29Daniel O.
30Celeste Leigh
au
0Lee, Alice W.
1Bomkamp, Ashley
2Bandera, Elisa V.
3Jensen, Allan
4Ramus, Susan J.
5Goodman, Marc T.
6Rossing, Mary Anne
7Modugno, Francesmary
8Moysich, Kirsten B.
9Chang‐Claude, Jenny
10Rudolph, Anja
11Gentry‐Maharaj, Aleksandra
12Terry, Kathryn L.
13Gayther, Simon A.
14Cramer, Daniel W.
15Doherty, Jennifer A.
16Schildkraut, Joellen M.
17Kjaer, Susanne K.
18Ness, Roberta B.
19Menon, Usha
20Berchuck, Andrew
21Mukherjee, Bhramar
22Roman, Lynda
23Pharoah, Paul D.
24Chenevix‐Trench, Georgia
25Olson, Sara
26Hogdall, Estrid
27Wu, Anna H.
28Pike, Malcolm C.
29Stram, Daniel O.
30Pearce, Celeste Leigh
atitleA splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
jtitleInternational Journal of Cancer
risdate20161215
volume139
issue12
spage2646
epage2654
issn0020-7136
eissn1097-0215
genrearticle
ristypeJOUR
abstractMenopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome‐wide association studies. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases and 4,051 controls across 10 case–control studies participating in the Ovarian Cancer Association Consortium (OCAC). Conditional logistic regression was used to determine the association between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer among ET users and non‐users separately and to test for statistical interaction. A splicing variant in , rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer ( = 0.013). ET users carrying the T allele had a 51% increased risk of disease (OR = 1.51, 95% CI 1.19–1.91), which was stronger for long‐term ET users of 10+ years (OR = 1.85, 95% CI 1.28–2.66,  = 0.034). Non‐users showed essentially no association (OR = 1.08, 95% CI 0.96–1.21). Two additional genomic regions harboring rs7207826 (C allele) and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid histotype ( = 0.021 and  = 0.037, respectively). Hence, three confirmed susceptibility variants were identified whose associations with ovarian cancer risk are modified by ET exposure; follow‐up is warranted given that these interactions are not adjusted for multiple comparisons. These findings, if validated, may elucidate the mechanism of action of these loci. What's new? Menopausal estrogen‐alone therapy (ET) is a well‐established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, with 18 ovarian cancer susceptibility loci already confirmed. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. This study identifies three confirmed susceptibility variants whose associations with ovarian cancer risk are modified by ET exposure. Of particular interest is the interaction with rs10069690, a functional variant located in . The findings, if validated, may elucidate the mechanism of action of these loci and be critical for future risk prediction modeling.
doi10.1002/ijc.30274
pages2646-2654
date2016-12-15